20 completed, 5 terminated, 1 withdrawn. 12 Phase 3, 6 Phase 4, 4 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 7, Terminated 4, Withdrawn 1 |
| Phase 4 | 6 | Completed 6 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Doripenem: new trials by email Literature Review of Doripenem trials Research Report on Doripenem
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria Polymyxin B, Polymyxin B + Doripenem - Bacteremia, Healthcare-associated Pneumonia | Phase 2 / Phase 3 | Withdrawn | Tan Tock Seng Hospital | 2015-01-01 | 2019-10-09 | |
| Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) - Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | Phase 3 | Completed | Pfizer | 598 | 2012-10-01 | 2017-09-06 |
| Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) - Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | Phase 3 | Completed | Pfizer | 641 | 2012-10-01 | 2017-09-06 |
| A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age Doripenem - Meningitis | Phase 1 | Terminated | Janssen Research & Development, LLC | 1 | 2012-03-01 | 2013-12-06 |
| Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients Doripenem or Piperacillin/Tazobactam - Septic Shock | Not applicable | Completed | University Hospital, Montpellier | 50 | 2012-02-01 | 2016-11-29 |
| Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem - Urinary Tract Infections | Phase 2 | Completed | Forest Laboratories | 217 | 2010-12-01 | 2014-02-03 |
| A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia Cefepime placebo, Cefepime, Doripenem - Pneumonia, Bacterial, Community-Acquired Infections | Phase 3 | Terminated | Janssen Research & Development, LLC | 7 | 2010-12-01 | 2014-07-15 |
| A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections Doripenem, Meropenem placebo, Meropenem - Abscess, Intra-Abdominal, Abdominal Abscess | Phase 3 | Terminated | Janssen Research & Development, LLC | 41 | 2010-12-01 | 2014-07-15 |
| A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections Doripenem, Doripenem placebo, Cefepime - Complicated Urinary Tract Infections or Pyelonephritis | Phase 3 | Terminated | Janssen Research & Development, LLC | 41 | 2010-12-01 | 2014-07-15 |
| The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia Doripenem - Ventilator-Associated Pneumonia | Phase 4 | Completed | Sutep Jaruratanasirikul | 12 | 2010-10-01 | 2011-11-09 |
| Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers Dori_MD_1 doripenem - Healthy | Phase 4 | Completed | Medical University of Vienna | 6 | 2010-08-01 | 2011-04-01 |
| Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients Doripenem, doripenem - Febrile Neutropenia | Phase 4 | Completed | Gary E. Stein, Pharm.D. | 12 | 2010-08-01 | 2015-10-14 |
| Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients Doripenem - Sepsis | Phase 4 | Completed | Emory University | 30 | 2010-04-01 | 2014-01-27 |
| A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections No intervention - Pneumonia, Bacterial, Nosocomial Infection | Completed | Janssen Pharmaceutica | 170 | 2009-11-01 | 2013-08-09 | |
| A Study of Doripenem in Infants Less Than 12 Weeks of Age Doripenem - Bacterial Infections | Phase 1 | Completed | Janssen Research & Development, LLC | 52 | 2009-10-01 | 2013-01-10 |
| PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region doripenem - Pneumonia, Pneumonia, Ventilator-Associated | Phase 4 | Completed | Janssen Research & Development, LLC | 216 | 2009-07-17 | 2024-11-19 |
| A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Doripenem - Infection, Cross Infection | Phase 4 | Completed | Janssen-Cilag Ltd.,Thailand | 270 | 2009-06-01 | 2013-10-30 |
| Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects Doripenem - Healthy | Phase 1 | Completed | Keith A. Rodvold | 40 | 2009-06-01 | 2013-03-14 |
| To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia Doripenem, Imipenem-Cilastatin, Placebo - Ventilator-Associated Pneumonia | Phase 3 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 274 | 2008-04-01 | 2012-12-28 |
| A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia Imipenem/cilastatin, Doripenem - Pneumonia, Ventilator-Associated, Pneumonia, Bacterial | Phase 2 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 146 | 2007-10-01 | 2019-03-19 |
Showing 20 of 26. Sign in to see all of them.
Pneumonia, Ventilator-Associated (10) · Healthcare-Associated Pneumonia (5) · Pneumonia (5) · Urinary Tract Infections (5) · Bacterial Infections (4) · Cross Infection (4) · Infections (4) · Pneumonia, Bacterial (4) · Appendicitis (3) · Intraabdominal Infections (3) · Peritonitis (3) · Abdominal Abscess (2) · Bacterial Infections and Mycoses (2) · Cholecystitis (2) · Ileus (2)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (7) · Janssen Research & Development, LLC (6) · Pfizer (2) · Emory University (1) · Forest Laboratories (1) · Gary E. Stein, Pharm.D. (1) · Janssen Pharmaceutica (1) · Janssen-Cilag Ltd.,Thailand (1) · Keith A. Rodvold (1) · Medical University of Vienna (1) · PriCara, Unit of Ortho-McNeil, Inc. (1) · Sutep Jaruratanasirikul (1) · Tan Tock Seng Hospital (1) · University Hospital, Montpellier (1)
United States (12) · Argentina (7) · Ukraine (6) · Brazil (5) · Mexico (5) · Poland (5) · Russia (5) · Germany (4) · Belgium (3) · Bulgaria (3) · Chile (3) · Colombia (3) · Croatia (3) · Czechia (3) · France (3)
Paul Newell, MBBS, MRCP (2) · David Lye, MBBS, FRACP (1) · Gary Stein, PharmD (1) · Jeffrey Salomone, MD (1) · Keith A. Rodvold, Pharm.D. (1) · Larry H. Danziger, Pharm.D. (1) · Mark H. Gotfried, M.D. (1)
PMID 19670912, PMID 20211892, PMID 20459721, PMID 27313268, PMID 29912399, PMID 30061279, PMID 30221827, PMID 32602065, PMID 18549664, PMID 21303745, PMID 23148736, PMID 24636429, PMID 26014957, PMID 37700689
2009 (3)